|
Market Cap (4-Jun) $4,133,080,064 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (26-May) 50,730,266 (14.95%) (3rd) |
|
52w High $27.40 |
52w Low $8.26 |
P/E 2,500.00 |
EPS -0.03 |
A news article has been posted about Telix Pharmaceuticals on the AFR. The article was published around , on 28 October 2024 at 2:26am.
Gift 5 articles to anyone you choose each month when you subscribe. Christian Behrenbruch, the co-founder and chief executive of $7 billion cancer diagnostic giant Telix Pharmaceuticals, has lashed out at Australia’s ability to make next-generation drugs ...
Read ArticleTLX was $11.22 at the close of trade on 30 June 2023
| Recent Articles about ASX:TLX | |
|---|---|
| 22-May | Telix Annual General Meeting Chairman and CEO Addresses
company-announcements.afr.com |
| 22-May | Telix Results of Annual General Meeting
company-announcements.afr.com |
| 21-May | Notice of change of interests of substantial holder
company-announcements.afr.com |
| 21-May | Appendix 3X - Initial Director's Interest Notice - AFR
company-announcements.afr.com |
| 4-May | cyclopharm - AFR
company-announcements.afr.com |
| 4-May | Telix Successfully Prices and Upsizes US$600 Million Convertible ...
company-announcements.afr.com |
| 1-May | Appendix 3Y Change of Director's Interest Notice
company-announcements.afr.com |
| 28-Apr | Educational Webinar: Unlocking the Potential of PSMA Therapy, A ...
company-announcements.afr.com |
| 26-Apr | Telephone 02 9994 7000 - AFR
company-announcements.afr.com |
| 23-Apr | Telix Announces Settlement of US$600 Million Convertible Bonds
company-announcements.afr.com |
| Tracked |
Find all articles about Telix Pharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.
Telix Pharmaceuticals 